$7.96
-0.68 (-7.87%)
Open$8.69
Previous Close$8.64
Day High$8.87
Day Low$7.76
52W High$17.43
52W Low$5.06
Volume—
Avg Volume483.5K
Market Cap109.50M
P/E Ratio—
EPS$-4.20
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+210.2% upside
Current
$7.96
$7.96
Target
$24.69
$24.69
$14.59
$24.69 avg
$25.91
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.96M | 11.88M | 13.51M |
| Net Income | 575.0K | 486.8K | 473.9K |
| Profit Margin | 4.4% | 4.1% | 3.5% |
| EBITDA | 905.5K | 814.6K | 969.2K |
| Free Cash Flow | 454.1K | 555.8K | 696.0K |
| Rev Growth | -0.8% | +15.7% | +3.2% |
| Debt/Equity | 0.71 | 1.01 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $262.82 | +1.11% | 72.8 | 459.33B |
| AMGN | Amgen Inc | $403.04 | -1.04% | 25.1 | 219.33B |
| GILD | Gilead Sciences Inc | $144.74 | -1.87% | — | 179.15B |
| VRTX | Vertex Pharmaceuticals Inc | $504.73 | -0.40% | 30.1 | 132.51B |
| REGN | Regeneron Pharmaceuticals | $735.20 | +0.05% | 17.4 | 75.36B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.72 | -4.96% | 36.9 | 29.82B |